Perspective · 3 Apr 2025
Research articlePublished 2012
Therapeutic Vaccination of Treatment-Failed TB Patients on andldquo;Palliativeandtrdquo; Support Consisting of Isoniazid and Rifampicin
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Open label phase 2b retrospectively controlled trial was conducted in 72 treatment-failed TB patients on socalled palliative support consisting of isoniazid (H) and rifampicin (R) with or without adjunct immunotherapy. The intervention group (N=36) received once-daily pill of V-5 Immunitor (V5) and comparison control (N=36) received HR only. The subjects in V5 and control groups had miliary: cavitary: MDR-TB: DR-TB: TB/HIV at 10: 26: 5: 4: 1 and 14: 22: 6: 6: 2 ratios, respectively. After 3 months 69.4% of V5-treated patients experienced negative sputum smear conversion (P<0.0001) vs. 16.7% (P=0.02) in comparison group who were treated for 3.5 months on average. 9 out of 10 V5 recipients with drug-resistant TB and TB/HIV became sputum negative, whereas none of 14 patients with same diagnosis converted (P<0.0001; OR 1732; 100-30008 at 95% CI). TB-associated inflammation was downregulated by V5 as shown by normalization of leukocytosis 7.9 vs. 6.2 x109/L (P=0.005) and decreased erythrocyte sedimentation rate 22.7 vs. 13.3 mm/h (P<0.0001), whereas among HR recipients changes were smaller, i.e., 7.2 vs. 7.5 x109/L (P=0.49) and 26.4 vs. 22.5 mm/h (P<0.0001). The body °C temperature was reduced from 37.4 ± 0.5 to 37.1 ± 0.3 (P=0.001) and from 37.7 ± 0.5 to 37.2 ± 0.5 (P=0.0002) in V5 and control respectively. In V5 arm average body weight accrual 2.2 ± 1.7 kg (P<0.0001) was higher than 0.08 ± 1.1 kg in control. No adverse effects or reactivation of disease were seen at any time. V5 is safe and in combination with simple two-drug regimen was highly effective as an immune adjunct for management of treatment-failed and/or drug-resistant TB.
Subjects
Infectious DiseasesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Mycobacterial Diseases.
Perspective · 3 Apr 2025
Human Networks as Pathways for Tuberculosis Infection
Perspective · 3 Apr 2025
Multidrug-Resistant Tuberculosis affecting Pediatric Populations
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalMycobacterial Diseases
- SubjectInfectious Diseases
- BylineArticles whose byline prints “Arjanova OV”
- BylineArticles whose byline prints “Butov DA”
- BylineArticles whose byline prints “Prihoda ND”
- BylineArticles whose byline prints “Zaitzeva SI”
- BylineArticles whose byline prints “Yurchenko LV”
- BylineArticles whose byline prints “Sokolenko NI”
- BylineArticles whose byline prints “Stepanenko AL”
- BylineArticles whose byline prints “Butova TS”
